We are proud to be the Exclusive Diamond Sponsor of the 5th World Congress of Paediatric Ophthalmology & Strabismus from July 11-13 in Kuala Lumpur, Malaysia, to share the latest research findings and insights on myopia management at our lunch symposia. Join us to hear from international experts at our first session on 11th July at 13:00 – 14:00 where we will showcase our Essilor Stellest lens five-year clinical trial results and latest evidence-based strategies in combination with low-dose atropine. Our second session on 13th July at 12:15 – 13:15 will present novel approaches in myopia management. We look forward to welcoming you at booth G001! #WeAreEssilorLuxottica
EssilorLuxottica’s Post
More Relevant Posts
-
🌟 At the forefront of ophthalmology: Dr. David Eichenbaum shares compelling results from a Phase IIB clinical trial at Retina World Congress. The study highlights Sozinibercept’s potential when combined with Ranibizumab, showing significant improvements in visual acuity for patients with specific types of macular lesions. This promising advancement could redefine treatment standards for neovascular macular degeneration by targeting both VEGF-A and additional pathways. #RWC2024 #OphthalmologyInnovation #ClinicalTrials Genentech Opthea RIWC24: Retina International World Congress 2024
To view or add a comment, sign in
-
LAST CALL: Urgent Extension for Abstract Submission! Time is running out! We're extending the abstract submission for OSWI's 35th Congress, but the window is closing FAST. You now have until January 14, 2024, @ midnight! This is YOUR moment to make a mark on the global ophthalmology stage. Don't let this opportunity slip away – submit your abstract NOW to be part of the most thrilling event in the field! Urgency is in the air! Act NOW and be a pivotal force in shaping the future of ophthalmology! The clock is ticking loudly! #OSWI35thCongress #LastCallAbstracts #OphthalmologyInnovation
To view or add a comment, sign in
-
-
Thanks to curated #RWD, we're gaining insights into cataracts, which are the leading cause of vision loss in the U.S. Learn how our recent partnership with the FDA and the American Academy of Ophthalmology led to major findings surrounding #IOL use among young patients with cataracts: https://hubs.la/Q02zhLTz0
To view or add a comment, sign in
-
-
A poster summarizing a clinical study with the innovative and revolutionary treatment of dry eye – RP501 – attracted great interest at the annual conference Association for Research in Vision and Ophthalmology, ARVO, in Seattle, USA. The poster was presented by Assoc. Prof. Dr. Gerhard Garhöfer, who was the principal investigator in the study. “I am very pleased with the positive response from the conference attendees, especially for the clinical results of the study which showed that RP501 has a unique mechanism of action and an innovative formulation that can help people suffering from mild to moderate dry eye. RP501 has strong potential to meet the high demand for clinical efficacy and ease of use that consumers demand,” says Assoc. Prof. Dr. Gerhard Garhöfer at the Medical University of Vienna. RP501 is being developed to be an effective and user-friendly over-the-counter thermogel for the temporary relief of dry eye, a condition that affects more than 300 million people worldwide. The results of a clinical study show that RP501 is safe, provides a significant therapeutic effect already at a dosage of 1-2 drops per day and is convenient to use – characteristics that consumers consider the most important parameters for a dry eye product. The study was completed in the spring of 2023 and is presented at ARVO under the title: “Assessment of safety, tolerability and efficacy of RP501 eye drops in patients with dry eye disease and subjects wearing contact lenses with lens discomfort.” #ARVO2024 #dryeyes #DED #innovation #RP501 #visionresearch #ophthalmology
To view or add a comment, sign in
-
-
Advancing Solutions for Global Antibiotic Resistance in ophthalmology Congratulations to all the TEAM on the successful publication of the randomized clinical trial on antiseptic use in ophthalmology as prophylactic treatment! Antiseptic drops are able to reduce significantly ocular surface bacterial load. One step closer to addressing the global challenge of antibiotic resistance ! #ResearchExcellence #OphthalmologyAdvancements ESASO
To view or add a comment, sign in
-
-
Here is a link to my ARVO session info and abstract. I would love it if you'd stop by to chat! https://lnkd.in/ejZX-s9T
Those attending the Association for Research in Vision and Ophthalmology (ARVO) this weekend, check out our fellow Curtis Martin, M.D. presenting some of our data regarding "The Performance of Trifocal Intraocular Lens Implantation in Highly Myopic Patients With or Without Astigmatism" It is his first of many ARVO presentations which is scheduled for 5/5/24 from 1 - 2:45 pm. Program Number: 544 - A0183. Ask him some questions as we will use any feedback to help modify the current manuscript. Christopher Shelby, M.D., Wyche T. Coleman III, MD, Brittany DeNaro, Thomas M. Catapano, Willis Knighton Health, Alcon #Research #Ophthalmology #PanOptix #Cataractsurgery
To view or add a comment, sign in
-
One of the ways to stay ahead in ophthalmology clinical research is by keeping up with the latest NEI findings. At True North, we leverage this knowledge to design more effective trials. What recent eye research excites you? Share below. #eyeinnovation #clinicalresearch #contractresearchorganization National Eye Institute (NEI)
To view or add a comment, sign in
-
Pr3vent's cofounder and CEO, Jochen Kumm, is attending the American Academy of Ophthalmology 2023 Expo Nov 3-6 at the Moscone Center in San Francisco . If you'd like to explore how Pr3vent is changing infant vision health, send a message to Jochen Kumm He is excited to share insights on our groundbreaking technology and its impact on early detection of vision disorders. Let's connect and discuss the future of ophthalmology! #AAO2023 #Pr3vent #Ophthalmology
To view or add a comment, sign in
-
-
Great news! We recorded the interactive session, so you can still benefit from all the insights we gained. 🎉 📽️ Watch the replay: https://bit.ly/3S3h2y3
🚀 Last week we held a very interesting webinar on #IBEX multiplex #immunohistochemistry with Dr. Amar TAMRA, PhD from Fluigent & Dr. Colin Chu from the UCL Institute of Ophthalmology, UK. 🔬 The good news is that we recorded the interactive session, so you can still take advantage of everything we learned. 🎉 📽️ Wtach the replay: https://bit.ly/3S3h2y3 Join us on Linkedin or on our Newsletter to be the first to know about our upcoming webinars this year. 👉https://bit.ly/3VY4XLS We look forward to seeing you next time! 👋 #Microfluidics hashtag#IBEX hashtag#Webinar hashtag#BiotechInnovation hashtag#NIH
To view or add a comment, sign in
-